Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cprit Awards And Administration topic
No spam. Unsubscribe anytime.
CPRIT oversight committee approves 53 academic grant recommendations and several administrative actions
Summary
At the oversight committee meeting, the board approved a slate of academic research awards, delegated contract authority to the CEO, approved product development RFAs for FY2026 and made several committee appointments. One application (RP250278) was voted on separately because an oversight member reported a conflict of interest.
The Cancer Prevention and Research Institute of Texas (CPRIT) oversight committee approved a package of grant and administrative actions at its meeting, including academic research awards, product development requests for applications (RFAs), committee appointments and a delegation of contract authority to the chief executive officer.
Why it matters: The committee’s votes authorize award negotiations and contracts that will advance research and prevention activities across Texas and set the agency’s product development funding priorities for FY2026.
Key votes and outcomes
- Minutes: The committee approved the draft minutes from the Nov. 20 oversight committee meeting (motion carried; recorded as approved on the record).
- RP250278 (single application): The committee took a separate recorded vote for application RP250278 because Dr. Rosenfeld reported a conflict of interest. The motion to approve the PICC recommendation for RP250278 carried; Dr. Rosenfeld did not vote on that recommendation and was noted as abstaining/recused for that item.
- Academic research slates (remaining 52 recommendations): The oversight committee approved the remaining 52 academic research award recommendations across multiple mechanisms (collaborative action center, core facility awards, individual investigator research awards including those for children and adolescents, computational systems biology, clinical trials, prevention and early detection, and recruitment awards). The chair requested a single vote to approve all remaining slates; the motion carried.
- Delegation of contract authority: The committee delegated authority to the CPRIT CEO to negotiate and sign contracts on behalf of CPRIT; the motion carried.
- Product development RFAs: The oversight committee approved the proposed FY2026 product development RFAs (mechanisms described by staff) and a supplemental award RFA for current product development grantees; the motions carried.
- Committee appointments and certifications: The committee approved the CEO’s appointments to the Scientific Research and Prevention Program Committees and three appointments to the Clinical Trials Advisory Committee. The chief compliance officer certified that the award slates complied with CPRIT statute and administrative rules prior to the votes.
- Rule adoption: The committee adopted final rule changes to Texas Administrative Code Chapter 703 as presented (published previously; no public comments were received) and authorized filing with the secretary of state.
What the record shows: In several votes the meeting minutes record that the motions carried with the required two‑thirds majority of members present and voting; the transcript shows the chair announcing approval or that the motion carried but does not list numeric roll‑call tallies for most votes. The committee explicitly recorded that Dr. Rosenfeld did not vote on RP250278 because of a conflict of interest.
Provenance: The committee’s motions and votes are recorded in the meeting transcript where staff presented the award slates, compliance certification and the chair called for motions and votes. Specific vote actions and the separate vote for RP250278 are included in the transcript excerpt referenced below.
Ending: Committee members authorized staff to proceed with contract negotiations and to implement the approved RFAs and awards; staff were directed to finalize contract documents and move forward with grant administration.
